Moti Haim: Transforming AF Care in the Elderly
Moti Haim, Professor and Director of Cardiology at Soroka Medical Center, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in BMJ Journals, adding:
”Excited to share our new nationwide study, just published in BMJ Open!
We analyzed a decade of electronic health records (2010–2020) for 45,820 elderly patients (median age 83) with atrial fibrillation to look at real-world trends and clinical outcomes during the DOAC era.
Key findings:
Practice Shift: Initial OAC prescriptions grew from 31 percent in 2010 (all warfarin) to 66 percent in 2019 (mostly DOACs).
DOAC Benefits: DOAC use was associated with lower risks of ischemic stroke and gastrointestinal bleeding compared to non-users.
DOACs vs. Warfarin: DOACs outperformed warfarin across stroke, bleeding, and mortality outcomes.
Mortality Risk: Patients receiving no OAC therapy faced the highest mortality rates.
I am very proud of this work and want to congratulate and thank my brilliant co-authors. It has been a true privilege working with such a dedicated team.”
Title: Direct oral anticoagulants in elderly patients with atrial fibrillation: a decade-long nationwide retrospective cohort study
Authors: Hilmi Alnsasra, Gal Tsaban, Daniel Ostrovsky, Noa Livne, Blake Filderman, Yaakov Henkin, Zaza Iakobishvili, Yoav Arnson, Alon Eisen, Yiska Weisband, Jorge Schliamser, Moti Haim
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 12, 2026, 17:15Cedric Hermans: Identifying and Diagnosing Hemophilia Carriers and Affected Females
-
Oct 12, 2026, 17:01Bianca Rocca: Evaluating Factor XI Inhibition Lessons from LIBREXIA-ACS
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026
-
Oct 12, 2026, 10:36PAI-1 Inhibition as a New Strategy for Enhancing Fibrinolysis and Clot Resolution